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Accepted 11 March 2014Graft versus host disease (GVHD) is a relatively frequent,
life-threatening complication of allogeneic hematopoietic
stem cell transplantations (HSCT). Despite signiﬁcant effort
in understanding the pathogenesis, its treatment is largely
unsatisfactory and has made little progress [1-3]. Chronic
GVHD is not less frightening and is long lasting, again with
poor overall success of treatment [4] and, as indicated by
patients themselves, chronic GVHD can be worse than the
original leukemia. Therefore, prevention of GVHD has been
and still is the primary object of many clinical trials. In vivo
T cell depletion with multispeciﬁc antibodies, such as
antithymocyte globulin (ATG), has been quite successful in
preventing both acute and chronic GVHD [5]. In this issue of
Biology of Blood and Marrow Transplantation [6], the French
Society for Stem Cell Transplantation and Cell Therapy
(SFGM) reports on 242 patients with progressive myelodys-
plastic syndrome (MDS) who underwent transplantation
with or without ATG in the conditioning regimen. They show
a signiﬁcantly reduced risk of acute GVHD and a borderline
reduction of chronic GVHD in patients receiving ATG;
survival, event-free survival and relapse were comparable.
This study adds to the signiﬁcant amount of published
data on the use of ATG in the conditioning regimen. Most, if
not all, prospective and retrospective studies report a
reduction of acute and/or chronic GVHD [5] in patients
receiving ATG, without a detrimental effect on survival. In
other words, the reduction of GVHD is not associated with
increased risk of relapse [6]. In particular, 2 prospective
studies in patients receiving unrelated donor grafts have
randomized 310 patients overall to receive or not to receive
ATG [7,8]. Patients receiving ATG had 20% less acute GVHD
grade II to IV (P ¼ .0004), 15% less grade III and IV acute
GVHD (P ¼ .0007), 20% less chronic GVHD (P < .0001), and
30% less extensive chronic GVHD (P < .00001). Relapse and
survival were comparable in patients receiving or not
receiving ATG. More patients in the ATG group could dis-
continue immunosuppressive therapy early, had Karnofsky
scores >90, and were less likely to have chronic lungFinancial disclosure: See Acknowledgments on page 598.
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very important endpoints, mostly for the patient, but also
for the management of transplant recipients in outpatient
clinics: having 10% or 40% patients with extensive chronic
GVHD makes a big difference in terms of quality of life, cost,
and involvement of the transplantation team.
Sowhy is everybody not using ATG in the unrelated donor
setting, or perhaps also in sibling peripheral blood grafts?
One reason is a higher risk of infections, particularly, but not
only, viral infections. Epstein Barr virus, for example, is a
signiﬁcant problem, clearly associated with the use of ATG,
possibly leading to lymphoproliferative disorders. We have
now solved the problem with the use of prophylactic ritux-
imab (200 mg ﬁxed dose) on day 5 after transplantation [10].
A second reason for not using ATG is the increased risk of
relapse, reported in some studies, which is contradicted by
the 2 randomized studies [7,8] and conﬁrmed by this retro-
spective report of the SFGM-TC in patients with progressive
MDS [6]. A third reason is that survival is not improved,
despite a reduction of acute and chronic GVHD. This is true in
the short term [7,8] but it may be untrue 10 years later [9].
Nevertheless, if survival is unchanged, I would hold this in
favor of using ATG in the conditioning regimen because of
the reduction of acute and, most of all, chronic GVHD. Sowhy
not use ATG, not only in the unrelated donor setting, but also
in sibling transplantation, as suggested by the SFGM report
[6] and others [11]? The latter group has now completed a
prospective randomized study with over 200 sibling
peripheral blood transplant recipients randomized to receive
or not to receive ATG in the conditioning regimen. Results
should be available this year.
The dose of ATG remains a critical issue. In the SFGM
report, most patients received 5 mg/kg total dose of Thy-
moglobulin (Sanoﬁ Aventis, Paris, France), which is an in-
termediate dose, and the number of patients was too small to
test the effect of different doses of ATG. The timing of ATG is
also critical and, perhaps, more important than dose: the
closer to transplantation, the greater the effect on host T cells
and, therefore, the protective effect on GVHD.
Finally, are different brands of ATG different? Currently
there are three ATG preparations in clinical use: Thymoglo-
bulin (rabbit ATG used in the SFGM study), ATG F (rabbit ATG,
used in the randomized German study), and ATGAM (horse
ATG). There has been no head-to-head comparison. However,
despite differences in potency and speciﬁcity between Thy-
moglobulin and ATG-F, the two prospective randomized
studies, oneusingThymoglobulin [9] and theother usingATG-
F [8], have comeexactly to the same conclusion: a reduction of
extensive chronic GVHD from 41% to 15% in one trial [9] and
from 45% to 12% in the other [8]. It is amazing that two pro-
spective randomized studies, performed 10 years apartdwith
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brand of rabbit ATGdwould both come to exactly the same
protective effect on GVHD. Survival was also quite similar in
the twostudies, furtherconﬁrming that theprotective effectof
ATG on GVHD is not the result of a magic preparation, but
rather of downregulation of host T cell function.
In conclusion, the report of the SFGM [6] adds further
evidence to the fact that ATG protects against GVHD without
a detrimental effect on relapse and survival. So why not use
ATG for all unrelated donor transplantations and perhaps
also for sibling peripheral blood grafts? If I were a patient,
ready to be admitted for an allogeneic transplantation, say, a
peripheral blood graft from an unrelated donor, I would be
aware of a signiﬁcant risk of acute and chronic GVHD, and I
would like to be protected as much as possible. ATG is
perhaps the best available choice, together with alemtuzu-
mab, to reduce the risk of GVHD morbidity.ACKNOWLEDGMENTS
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plants from HLA-haploidentical donors performed using
conventional pharmacologic graft-versus-host disease
(GVHD) prophylaxis (eg, calcineurin antagonist and meth-
otrexate) were largely unsuccessful because of severe post-
transplant alloreactivity [1,2]. More successful strategies for
transplants from haplodentical donors have included
extensive ex vivo and/or in vivo T cell depletion [3-5], ormore recently, T cellereplete grafts using post-transplant
cyclophosphamide (ptCy) to control alloreactivity [6-9].
Whereas mobilized donor peripheral blood stem cells
(PBSC) have been the preferred graft source for strategies
that involve T cell depletion, unmobilized donor marrow
has been the graft source with T cellereplete transplants
utilizing ptCy. The reasons behind a preference for bone
marrow grafts in studies of T cellereplete haploidentical
transplants using ptCy are complex. They include the pio-
neering work in this ﬁeld at Johns Hopkins University,
where unmobilized bone marrow (BM) is the institutionally
preferred graft source for almost all transplants, and con-
cerns that the larger number of T cells typically present in
granulocyte-colony stimulating factore (G-CSF) mobilized
PBSC may overwhelm the ability of ptCy to suppress detri-
mental alloreactivity post-transplant.
However, several beneﬁts may be realized if mobilized
PBSC were shown to be safe in this setting. Speciﬁcally, the
scheduling challenges of bone marrow harvests in an era of
limited access to operating room and physician resources
